<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703127</url>
  </required_header>
  <id_info>
    <org_study_id>3/2020</org_study_id>
    <nct_id>NCT04703127</nct_id>
  </id_info>
  <brief_title>Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.</brief_title>
  <acronym>PE</acronym>
  <official_title>Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therefore, this study will aim to assess the effectiveness and tolerability of the on-demand&#xD;
      use of combined dapoxetine with tadalafil and combined dapoxetine with lidocaine 5% spray in&#xD;
      treatment of patients with lifelong premature ejaculation and non-responding to dapoxetine&#xD;
      alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be carried out on 60 patients with lifelong premature ejaculation and&#xD;
      non-responding to dapoxetine alone.&#xD;
&#xD;
      All patients will be equally divided into 2 groups (30 patients each). Group 1 was given&#xD;
      on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse. Group 1 was given&#xD;
      on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans&#xD;
      penis 10 minutes the wash before intercourse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All patients will be equally divided into 2 groups (30 patients each). Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse. Group 1 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>All patients will be equally divided into 2 groups (30 patients each).Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse. Group 1 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intravaginal ejaculatory latency time (IELT)</measure>
    <time_frame>0-8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Arabic Index of Premature Ejaculation (AIPE)</measure>
    <time_frame>0-8 week</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Premature Ejaculation</condition>
  <arm_group>
    <arm_group_label>Patients with lifelong premature ejaculation and non-responding to dapoxetine alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil and Combined Dapoxietine</intervention_name>
    <description>Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.</description>
    <arm_group_label>Patients with lifelong premature ejaculation and non-responding to dapoxetine alone</arm_group_label>
    <other_name>Tadalafil with Combined Dapoxietine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapoxietine and Combined Lidocaine 5% Spray</intervention_name>
    <description>Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.</description>
    <arm_group_label>Patients with Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.</arm_group_label>
    <other_name>Dapoxietine With Lidocaine 5% Spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  lifelong premature ejaculation and non-responding to dapoxetine alone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetes mellitus,&#xD;
&#xD;
          -  chronic prostatitis,&#xD;
&#xD;
          -  Advanced renal or hepatic diseases&#xD;
&#xD;
          -  neurological diseases&#xD;
&#xD;
          -  C.N.S. medications&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male Patients with PE</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed A El-Hamd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed A Abu El-Hamd, MD</last_name>
    <phone>01004139060</phone>
    <email>Mohammedadva@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed Abu El-Hamd, MD</last_name>
    <phone>01004139060</phone>
    <email>Mohammedadva@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mohammed Abu El-Hamd</name>
      <address>
        <city>Sohag</city>
        <zip>82524</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed A Abu El-Hamd, MD</last_name>
      <phone>01004139060</phone>
      <email>Mohammedadva@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Mohammed Abu El-Hamd</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology, Venereology and Andrology Department, Faculty of Medicine, Sohag University, Egypt.</investigator_title>
  </responsible_party>
  <keyword>Premature Ejaculation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Premature Ejaculation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

